Summary of Consolidated Financial Results [IFRS]
for the First Six Months (Semi-Annual Period) of the Fiscal Year Ending March 31, 2027

November 10, 2026

Listed company name	:	Sysmex Corporation
Code	:	6869
Listed stock exchanges	:	Tokyo Stock Exchange
URL	:	www.sysmex.co.jp/en
Company representative	:	Iwane Matsui, President
Contact	:	Takuro Minami, Executive Vice President of Corporate Business Administration
Phone	:	078(265)-0500
Scheduled date for filing of semi-annual report	:	November 12, 2026
Scheduled date for dividend payment	:	December 4, 2026
Preparation of supplementary material for semi-annual earnings	:	Yes
Holding of earnings announcement	:	Yes

(Unit: Millions of Yen)

1. Results for the First Six Months (Semi-Annual Period) of the Fiscal Year Ending March 31, 2027

(1) Operating results

(% changes as compared with the semi-annual period of the previous fiscal year)

	Net Sales		Operating profit		Profit before tax		Profit	
Six months ended Sep. 30, 2026	272,822	17.3%	33,428	1.4%	29,137	(2.7)%	17,818	(5.5)%
Six months ended Sep. 30, 2025	232,527	(4.1)%	32,957	(25.9)%	29,955	(21.7)%	18,862	(27.2)%

	Profit attributable to owners of the parent		Total comprehensive income		Basic earnings per share (Yen)	Diluted earnings per share (Yen)
Six months ended Sep. 30, 2026	17,933	(5.7)%	15,660	(47.9)%	29.47	29.47
Six months ended Sep. 30, 2025	19,019	(26.9)%	30,038	71.3%	30.50	30.50

(2) Financial condition

	Total assets	Total equity	Equity attributable to owners of the parent	Equity attributable to owners of the parent to total assets
As of Sep. 30, 2026	735,394	481,704	481,143	65.4%
As of Mar. 31, 2026	707,532	505,676	505,000	71.4%

2. Dividend

	Dividend per share				
	First quarter (Yen)	Second quarter (Yen)	Third quarter (Yen)	Year-end (Yen)	Annual (Yen)
Year ended Mar. 31, 2026	—	19.00	—	19.00	38.00
Year ending Mar. 31, 2027	—	20.00			
Year ending Mar. 31, 2027 (Forecast)			—	20.00	40.00

Note: Revision of dividends forecast for this period: No

3. Financial Forecast for the Year Ending March 31, 2027

(% changes as compared with the previous fiscal year)

	Net Sales		Operating profit		Profit before tax		Profit attributable to owners of the parent		Basic earnings per share (Yen)
Year ending Mar. 31, 2027	550,000	10.0%	68,500	32.2%	61,500	25.4%	40,000	12.8%	66.06

Note: Revision of financial forecast for this period: Yes

4. Other Information

(1) Significant changes in scope of consolidation: Yes
Newly included: One company (Sysmex BioMajesty Co., Ltd)

(2) Changes in accounting policies and accounting estimates
1) Changes in accounting policies required by IFRS: No
2) Other changes in accounting policies: No
3) Changes in accounting estimates: No

(3) Number of outstanding stock (common stock)
1) Number of outstanding stock at the end of each fiscal period (including treasury stock):
608,341,876 shares as of Sep.30, 2026; 629,480,076 shares as of Mar. 31, 2026
2) Number of treasury stock at the end of each fiscal period:
6,268,989 shares as of Sep. 30, 2026; 7,995,365 shares as of Mar. 31, 2026
3) Average number of outstanding stock for each period (semi-annual period):
608,443,745 shares for the six months ended Sep. 30, 2026
623,485,229 shares for the six months ended Sep. 30, 2025

Note: Sysmex Corporation (the "Company") has introduced Executive Compensation BIP Trust and Stock-Granting Employee Stock Ownership Plan (ESOP) Trust. Company shares held by the trust are included in treasury stock and are excluded from calculations of the number of treasury stock at the end of the fiscal period and the average number of outstanding stock for the period.

* Summaries of semi-annual financial results are exempt from review conducted by certified public accountants or an audit firm.

* Explanation regarding the appropriate use of financial forecast and other information

1. The forecasts and future projections contained herein have been prepared on the basis of rational decisions given the information available as of the date of announcement of this document. These forecasts do not represent a commitment by the Company, and actual performance may differ substantially from forecasts for a variety of reasons. Please refer to "3) Consolidated financial forecast" within "1. Qualitative information on semi-annual financial results" on page 4 of the attachment to this document for cautionary statements concerning the conditions and performance forecasts that serve as the basis for these forecasts.
2. Supplementary financial materials (in Japanese and English) will be posted on the Sysmex website on Tuesday, November 10, 2026.

Content of Supplementary Materials

1. Qualitative information on semi-annual financial results 2
   1) Operating performance analysis 2
   2) Financial conditions analysis 3
   3) Consolidated financial forecast 4
2. Condensed semi-annual consolidated financial statements and notes 5
   1) Condensed semi-annual consolidated statement of financial position 5
   2) Condensed semi-annual consolidated statement of income 7
   3) Condensed semi-annual consolidated statement of comprehensive income 8
   4) Condensed semi-annual consolidated statement of changes in equity 9
   5) Condensed semi-annual consolidated statement of cash flows 11
   6) Notes to the condensed semi-annual consolidated financial statements 12
      1. Notes related to the going concern assumption 12
      2. Segment information 12

1. Qualitative information on semi-annual financial results

Future-related information contained in the text below is based on the Company's judgement as of the end of the fiscal period under review.

1) Operating performance analysis

The Sysmex Group's consolidated financial results for the first six months of the fiscal year ending March 31, 2027 are as follows.

Net sales by destination

		Six months ended Sep. 30, 2025		Six months ended Sep. 30, 2026		YoY (Previous period = 100)
		Amount (Millions of yen)	Percentage of total (%)	Amount (Millions of yen)	Percentage of total (%)	
Japan		25,435	10.9	36,069	13.2	141.8
	Americas	64,686	27.8	82,171	30.1	127.0
	EMEA (Europe, the Middle East, and Africa)	72,968	31.4	86,804	31.9	119.0
	China	43,282	18.7	38,861	14.2	89.8
	AP (Asia Pacific)	26,153	11.2	28,914	10.6	110.6
Overseas subtotal		207,092	89.1	236,752	86.8	114.3
Total		232,527	100.0	272,822	100.0	117.3

In Japan, sales in the clinical chemistry field increased following the start of business operations by Sysmex BioMajesty Co., Ltd., acquired from JEOL Ltd. As a result, sales in Japan were up 41.8% year on year, to ¥36,069 million. The ratio of sales in Japan increased 2.3 percentage points, to 13.2%.

Overseas, sales of hematology instruments, reagents, and maintenance services increased. This factor, coupled with depreciation of the yen in foreign exchange markets, caused overseas sales to rise 14.3%, to ¥236,752 million. The overseas sales ratio was down 2.3 percentage points, to 86.8%.

Selling, general and administrative (SG&A) expenses totaled ¥85,476 million, up 9.8% year on year, mainly due to increases in personnel accompanying the expansion of business. R&D expenses came to ¥14,226 million, up 7.7%. In addition, the Group recognized an impairment loss on goodwill and other assets arising from the business combination of Sysmex BioMajesty Co., Ltd.

As a result, on a consolidated basis for the first six months of the fiscal year ending March 31, 2027, net sales amounted to ¥272,822 million (up 17.3% year on year), operating profit was ¥33,428 million (up 1.4%), profit before tax was ¥29,137 million (down 2.7%), and profit attributable to owners of the parent totaled ¥17,933 million (down 5.7%).

Performance by segment

(1) Headquarters

In Japan, sales in the clinical chemistry field increased following the start of business operations by Sysmex BioMajesty Co., Ltd. In addition, sales of hematology and hemostasis reagents rose in South Korea. As a result, segment sales rose 34.8% year on year, to ¥51,727 million.

On the profit front, gross profit increased due to higher sales, but segment profit (operating profit) fell 12.5% year on year, to ¥10,385 million, mainly due to the recognition of an impairment loss and other factors.

(2) Americas RHQ

In North America, sales of instruments, reagents and maintenance services in the hematology field increased. In Central and South America, sales of hematology and urinalysis reagents grew mainly in Brazil. As a result, segment sales increased 26.1% year on year, to ¥77,109 million.

On the profit front, although SG&A expenses increased, higher net sales and an improvement in the cost of sales ratio pushed up segment profit (operating profit) 172.4% year on year, to ¥8,649 million.

(3) EMEA RHQ

Sales of instruments, reagents and maintenance services in the hematology and hemostasis fields increased, mainly in Europe. As a result, segment sales increased 19.0% year on year, to ¥83,960 million.

On the profit front, although SG&A expenses increased, the higher gross profit on increased sales boosted segment profit (operating profit) 37.5% year on year, to ¥7,869 million.

(4) China RHQ

Sales of instruments, reagents and maintenance services in the hemostasis field decreased due to the continuing impact of healthcare cost control policies, as did sales of instruments in the hematology field. As a result, segment sales fell 10.4% year on year, to ¥38,730 million.

On the profit front, lower sales caused gross profit to decline. Consequently, segment profit (operating profit) fell 39.3% year on year, to ¥3,452 million.

(5) Asia Pacific RHQ

Sales of reagents in the hematology and hemostasis fields increased, mainly in the Indian market. As a result, segment sales rose 10.7% year on year, to ¥21,294 million.

On the profit front, despite higher net sales, a deterioration in the cost of sales ratio and an increase in SG&A expenses caused segment profit (operating profit) to fall 22.7% year on year, to ¥2,801 million.

2) Financial conditions analysis

(1) Financial conditions

As of September 30, 2026, total assets amounted to ¥735,394 million, up ¥27,861 million from March 31, 2026. This increase was chiefly to increases of ¥36,518 million in cash and cash equivalents and ¥8,936 million in inventories, despite decreases of ¥8,210 million in trade and other receivables (current assets) and ¥6,744 million in income taxes receivable.

Meanwhile, total liabilities increased by ¥51,833 million from March 31, 2026, to ¥253,689 million. The main factors included increase of ¥49,643 million in long-term loans payable.

Total equity decreased by ¥23,971 million from March 31, 2026, to ¥481,704 million. This was mainly the result of a ¥22,268 million decrease in retained earnings, due to the cancellation of treasury shares and other factors. The equity attributable to owners of the parent to total assets was down 6.0 percentage points, from 71.4% as of March 31, 2026, to 65.4%.

(2) Cash flows

As of September 30, 2026, cash and cash equivalents amounted to ¥120,636 million, up ¥36,518 million from March 31, 2026.

Cash flows from various activities during the first six months of the fiscal year are described in more detail below.

(Cash flows from operating activities)

Net cash provided by operating activities was ¥67,094 million, up ¥29,032 million from the first six months of the preceding fiscal year. This was due mainly to profit before tax of ¥29,137 million (down ¥818 million year on year), depreciation and amortization of ¥23,808 million (up ¥975 million), impairment losses of ¥5,769 million (up ¥5,769 million), and a decrease in trade receivables of ¥11,482 million (down ¥4,309 million).

(Cash flows from investing activities)

Net cash used in investing activities was ¥33,002 million (up ¥6,397 million). This was attributable chiefly to purchases of property, plant and equipment of ¥13,325 million (down ¥2,319 million year on year), purchase of intangible assets of ¥7,830 million (down ¥2,180 million), purchase of investments accounted for using equity method of ¥2,850 million (up ¥2,850 million), and payments for acquisition of subsidiaries or other businesses of ¥9,346 million (up ¥9,346 million).

(Cash flows from financing activities)

Net cash provided by financing activities was ¥3,521 million (¥17,577 million used in the previous period). This was due mainly to proceeds from long-term loans payable of ¥50,000 million (up ¥50,000 million year on year), purchases of treasury shares of ¥27,859 million (up ¥26,981 million), and dividends paid of ¥11,808 million (up ¥1,207 million).

3) Consolidated financial forecast

For the Sysmex Group's consolidated financial forecast for the full fiscal year, please refer to the Announcement Regarding Revision of Full-Year Financial Forecasts for the Fiscal Year Ending March 31, 2027, announced today (November 10, 2026).

2. Condensed semi-annual consolidated financial statements and notes

1) Condensed semi-annual consolidated statement of financial position

(Unit: Millions of yen)

	As of March 31, 2026	As of September 30, 2026
Assets		
Current assets		
Cash and cash equivalents	84,117	120,636
Trade and other receivables	168,783	160,572
Inventories	95,613	104,550
Other short-term financial assets	775	933
Income taxes receivable	8,757	2,012
Other current assets	30,559	29,860
Total current assets	388,606	418,566
Non-current assets		
Property, plant and equipment	150,396	147,470
Goodwill	4,138	4,323
Intangible assets	93,173	92,175
Investments accounted for using the equity method	150	405
Trade and other receivables	34,756	36,794
Other long-term financial assets	14,025	13,514
Asset for retirement benefits	0	56
Other non-current assets	6,643	6,579
Deferred tax assets	15,641	15,507
Total non-current assets	318,925	316,827
Total assets	707,532	735,394

(Unit: Millions of yen)

	As of March 31, 2026	As of September 30, 2026
Liabilities and equity		
Liabilities		
Current liabilities		
Trade and other payables	34,116	30,617
Lease liabilities	9,555	9,560
Other current financial liabilities	1,316	4,720
Income taxes payable	2,980	6,482
Provisions	1,342	1,411
Contract liabilities	20,770	20,329
Accrued expenses	22,610	26,951
Accrued bonuses	14,976	11,774
Other current liabilities	11,591	11,272
Total current liabilities	119,259	123,121
Non-current liabilities		
Long-term loans payable	31,646	81,289
Lease liabilities	29,280	27,879
Other non-current financial liabilities	35	25
Liability for retirement benefits	2,238	3,106
Provisions	1,307	1,308
Other non-current liabilities	12,198	11,426
Deferred tax liabilities	5,889	5,531
Total non-current liabilities	82,596	130,568
Total liabilities	201,856	253,689
Equity		
Equity attributable to owners of the parent		
Capital stock	14,898	14,898
Capital surplus	21,114	20,869
Retained earnings	416,253	393,984
Treasury stock	(15,501)	(14,581)
Other components of equity	68,236	65,972
Total equity attributable to owners of the parent	505,000	481,143
Non-controlling interests	675	560
Total equity	505,676	481,704
Total liabilities and equity	707,532	735,394

2) Condensed semi-annual consolidated statement of income

(Unit: Millions of yen)

	Six months ended September 30, 2025	Six months ended September 30, 2026
Net sales	232,527	272,822
Cost of sales	109,970	132,387
Gross profit	122,556	140,434
Selling, general and administrative expenses	77,873	85,476
Research and development expenses	13,203	14,226
Impairment losses	—	5,769
Other operating income	1,974	1,295
Other operating expenses	496	2,828
Operating profit	32,957	33,428
Financial income	441	485
Financial expenses	1,814	2,708
Share of profit (loss) of associates accounted for using the equity method	(938)	(645)
Foreign exchange gain (loss)	(689)	(1,421)
Profit before tax	29,955	29,137
Income tax expense	11,092	11,319
Profit	18,862	17,818
Profit attributable to		
Owners of the parent	19,019	17,933
Non-controlling interests	(156)	(114)
Profit	18,862	17,818

(Unit: Yen)

Earnings per share		
Basic	30.50	29.47
Diluted	30.50	29.47

3) Condensed semi-annual consolidated statement of comprehensive income

(Unit: Millions of yen)

	Six months ended September 30, 2025	Six months ended September 30, 2026
Profit	18,862	17,818
Other comprehensive income		
Items that will not be reclassified subsequently to profit or loss		
Net gain on financial assets measured at fair value through other comprehensive income	585	293
Total	585	293
Items that may be reclassified subsequently to profit or loss		
Exchange differences on translation of foreign operations	10,573	(2,444)
Share of other comprehensive income of investments accounted for using the equity method	16	(5)
Total	10,590	(2,450)
Total other comprehensive income	11,175	(2,157)
Comprehensive income	30,038	15,660
Comprehensive income attributable to		
Owners of the parent	30,194	15,775
Non-controlling interests	(156)	(114)
Comprehensive income	30,038	15,660

4) Condensed semi-annual consolidated statement of changes in equity
Six months ended September 30, 2025

(Unit: Millions of yen)

	Equity attributable to owners of the parent						Non-controlling interests	Total equity
	Capital stock	Capital surplus	Retained earnings	Treasury stock	Other components of equity	Total		
As of April 1, 2025	14,887	20,960	402,820	(12,318)	37,425	463,776	758	464,534
Profit			19,019			19,019	(156)	18,862
Other comprehensive income					11,175	11,175		11,175
Comprehensive income	—	—	19,019	—	11,175	30,194	(156)	30,038
Issuance of share acquisition rights (Exercise of share acquisition rights)	10	6				16		16
Share-based payment transactions		46				46		46
Cash dividends			(10,601)			(10,601)		(10,601)
Purchase of treasury shares				(877)		(877)		(877)
Disposal of treasury shares		(31)		31		—		—
Cancellation of treasury shares						—		—
Transfer from retained earnings to capital surplus						—		—
Transfer to retained earnings			(41)		41	—		—
Total transactions with the owners	10	20	(10,642)	(846)	41	(11,416)	—	(11,416)
As of September 30, 2025	14,898	20,981	411,197	(13,165)	48,643	482,554	602	483,156

Six months ended September 30, 2026

(Unit: Millions of yen)

	Equity attributable to owners of the parent						Non-controlling interests	Total equity
	Capital stock	Capital surplus	Retained earnings	Treasury stock	Other components of equity	Total		
As of April 1, 2026	14,898	21,114	416,253	(15,501)	68,236	505,000	675	505,676
Profit			17,933			17,933	(114)	17,818
Other comprehensive income					(2,157)	(2,157)		(2,157)
Comprehensive income	—	—	17,933	—	(2,157)	15,775	(114)	15,660
Issuance of share acquisition rights (Exercise of share acquisition rights)						—		—
Share-based payment transactions		20				20		20
Cash dividends			(11,808)			(11,808)		(11,808)
Purchase of treasury shares				(27,859)		(27,859)		(27,859)
Disposal of treasury shares		(62)		77		14		14
Cancellation of treasury shares		(28,702)		28,702		—		—
Transfer from retained earnings to capital surplus		28,499	(28,499)			—		—
Transfer to retained earnings			106		(106)	—		—
Total transactions with the owners	—	(244)	(40,201)	919	(106)	(39,632)	—	(39,632)
As of September 30, 2026	14,898	20,869	393,984	(14,581)	65,972	481,143	560	481,704

5) Condensed semi-annual consolidated statement of cash flows

(Unit: Millions of yen)

	Six months ended September 30, 2025	Six months ended September 30, 2026
Cash flows from operating activities		
Profit before tax	29,955	29,137
Depreciation and amortization	22,832	23,808
Impairment losses (reversal)	—	5,769
Share of loss (profit) of associates accounted for using the equity method	938	645
Loss on retirement of non-current assets	157	442
Decrease (increase) in trade receivable	15,791	11,482
Decrease (increase) in advance payments	(962)	(1,130)
Decrease (increase) in inventories	(6,905)	(5,414)
Increase (decrease) in trade payable	215	(148)
Increase (decrease) in accounts payable–other	(2,453)	(2,345)
Increase (decrease) in contract liabilities	(986)	55
Increase (decrease) in accrued expenses	(1,927)	4,561
Decrease/increase in consumption taxes receivable/payable	1,887	4,796
Increase (decrease) in accrued bonuses	(4,464)	(3,303)
Other—net	(817)	1,148
Subtotal	53,260	69,505
Interest and dividend received	290	327
Interest paid	(1,098)	(1,731)
Income taxes paid	(14,389)	(1,006)
Net cash provided by (used in) operating activities	38,062	67,094
Cash flows from investing activities		
Purchases of property, plant and equipment	(15,645)	(13,325)
Purchases of intangible assets	(10,011)	(7,830)
Payments resulting in an increase in long-term prepaid expenses	(400)	(115)
Payments into time deposits	(352)	(818)
Proceeds from withdrawal of time deposits	539	741
Purchase of other financial assets	(1,229)	(373)
Proceeds from sale of other financial assets	0	1,299
Purchase of investments accounted for using equity method	—	(2,850)
Payments for acquisition of subsidiaries or other businesses	—	(9,346)
Other—net	495	(382)
Net cash provided by (used in) investing activities	(26,604)	(33,002)
Cash flows from financing activities		
Proceeds from long-term loans payable	—	50,000
Repayments of long-term loans payable	(356)	(356)
Proceeds from issuance of shares	16	—
Purchase of treasury shares	(877)	(27,859)
Dividends paid	(10,601)	(11,808)
Repayments of lease liabilities	(5,789)	(6,468)
Other—net	31	14
Net cash provided by (used in) financing activities	(17,577)	3,521
Effects of exchange rate changes on cash and cash equivalents	2,651	(1,094)
Net increase (decrease) in cash and cash equivalents	(3,468)	36,518
Cash and cash equivalents at the beginning of the term	89,570	84,117
Cash and cash equivalents at the end of the term	86,101	120,636

6) Notes to the condensed semi-annual consolidated financial statements

1. Notes related to the going concern assumption

Not applicable

2. Segment information

1) Overview of reportable segments

The reportable segments of the Company and its subsidiaries (the "Group") are the constituent business units for which separate financial data are available and that are examined on a regular basis for the purpose of enabling the Managing Board to allocate managerial resources and evaluate results of operations.

The Group is primarily engaged in the manufacture and sale of diagnostic instruments and reagents. These businesses are conducted in Japan and East Asia by Sysmex and in the Americas, EMEA, China, and the Asia Pacific by regional headquarters established therein. These companies formulate comprehensive strategies tailored to regional characteristics and conduct business activities accordingly. Some overseas subsidiaries are managed by the Company depending on the nature of their business.

The five managing company-specific segments are “Headquarters,” “Americas RHQ,” “EMEA RHQ,” “China RHQ,” and “AP RHQ.”

The companies included in these reportable segments are outlined below.

Reportable segments	Companies included in the reportable segments
Headquarters	Sysmex Corporation, Sysmex RA Co., Ltd., 13 other domestic subsidiaries, Oxford Gene Technology IP Limited, Sysmex Partec GmbH, Sysmex Korea Co., Ltd., 11 other overseas subsidiaries
Americas RHQ	Sysmex America, Inc., Sysmex Reagents America, Inc., Sysmex do Brasil Industria e Comercio Ltda., five other subsidiaries in the Americas
EMEA RHQ	Sysmex Europe SE, Sysmex Deutschland GmbH, Sysmex UK Limited, Sysmex France S.A.S., 25 other subsidiaries in the EMEA region
China RHQ	Sysmex Shanghai ltd., Jinan Sysmex Medical Electronics Co., Ltd., two other subsidiaries in China
AP RHQ	Sysmex Asia Pacific Pte Ltd., Sysmex India Pvt. Ltd., nine other subsidiaries in the Asia Pacific region

2) Segment profit and operating results

Profit and operating results from continuing operations by reportable segment of the Group are as follows;

Intersegment sales are determined based on market prices or costs of goods manufactured.

Accounting policies of reporting segments are consistent with the Group’s accounting policies indicated in the consolidated financial statements for the previous fiscal year.

Six months ended September 30, 2025

(Unit: Millions of yen)

	Reportable segment						Adjustments (Note 1)	Consolidated (Note 2)
	Head-quarters	Americas RHQ	EMEA RHQ	China RHQ	AP RHQ	Total		
Sales								
Sales to external customers	38,371	61,164	70,531	43,227	19,232	232,527	—	232,527
Intersegment sales	62,024	13	274	169	22	62,505	(62,505)	—
Total	100,395	61,177	70,806	43,397	19,255	295,033	(62,505)	232,527
Segment profit (loss)	11,874	3,175	5,721	5,688	3,626	30,086	2,871	32,957
Financial income	—	—	—	—	—	—	—	441
Financial expenses	—	—	—	—	—	—	—	1,814
Share of profit (loss) of associates accounted for using the equity method	—	—	—	—	—	—	—	(938)
Foreign exchange gain (loss)	—	—	—	—	—	—	—	(689)
Profit before tax	—	—	—	—	—	—	—	29,955
Income tax expense	—	—	—	—	—	—	—	11,092
Profit	—	—	—	—	—	—	—	18,862
Other information								
Impairment losses	—	—	—	—	—	—	—	—

Notes:

1. Segment profit (loss) adjustments of ¥2,871 million include ¥2,917 million for the unrealized gains on inventories and negative ¥46 million for the unrealized gains on non-current assets.
2. Segment profit (loss) is adjusted to coincide with operating profit in the condensed semi-annual consolidated statement of income.

Six months ended September 30, 2026

(Unit: Millions of yen)

	Reportable segment						Adjustments (Note 1)	Consolidated (Note 2)
	Head-quarters	Americas RHQ	EMEA RHQ	China RHQ	AP RHQ	Total		
Sales								
Sales to external customers	51,727	77,109	83,960	38,730	21,294	272,822	—	272,822
Intersegment sales	60,689	10	508	229	26	61,464	(61,464)	—
Total	112,416	77,120	84,468	38,960	21,320	334,286	(61,464)	272,822
Segment profit (loss)	10,385	8,649	7,869	3,452	2,801	33,159	269	33,428
Financial income	—	—	—	—	—	—	—	485
Financial expenses	—	—	—	—	—	—	—	2,708
Share of profit (loss) of associates accounted for using the equity method	—	—	—	—	—	—	—	(645)
Foreign exchange gain (loss)	—	—	—	—	—	—	—	(1,421)
Profit before tax	—	—	—	—	—	—	—	29,137
Income tax expense	—	—	—	—	—	—	—	11,319
Profit	—	—	—	—	—	—	—	17,818
Other information								
Impairment losses	5,769	—	—	—	—	5,769	—	5,769

Notes:

1. Segment profit (loss) adjustments of ¥269 million include ¥1,141 million for the unrealized gains on inventories and negative ¥872 million for the unrealized gains on non-current assets.
2. Segment profit (loss) is adjusted to coincide with operating profit in the condensed semi-annual consolidated statement of income.